Development of hepatitis B virus inhibitor AB-836 terminated due to safety concerns
ADC评论
November 7, 2022
AB-836, a next-generation oral hepatitis B virus (HBV) capsid inhibitor (class II capsid inhibitor) that Arbutus Biopharma is developing for the treatment of chronic hepatitis
